Asthma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797450
  • Drug Pipelines
  • 429 pages
  • Datamonitor Healthcare
1 of 3
The increasing availability of biologics will drive growth in the asthma market during 2015-24, but prescribing will be restricted to patients with severe persistent uncontrolled asthma.

This report addresses the following questions:

- Where will the newly approved Nucala and Cinqair be positioned in the treatment algorithm and will they directly compete with Xolair?
- What are pulmonologists’ views on the late-phase interleukin (IL) inhibitors and how will they differentiate between them?
- What clinical endpoints do pulmonologists want to see in trial programs of biologics?
- How will the loss of brand exclusivity impact leading inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) inhalers?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: ASTHMA IN THE US, JAPAN, AND 5EU

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Brand Forecasts
- Advair (fluticasone/salmeterol)
- benralizumab
- Breo (fluticasone furoate/vilanterol)
- Cinqair (reslizumab)
- Dulera (mometasone/formoterol)
- Flutiform (fluticasone/formoterol)
- Nucala (mepolizumab)
- Singulair (montelukast)
- Spiriva (tiotropium)
- Symbicort (budesonide/formoterol)
- Xolair (omalizumab)
- Primary Research Methodology

TREATMENT: ASTHMA

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Impact of Generics
- Unmet Needs in Asthma

EPIDEMIOLOGY: ASTHMA

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: ASTHMA

- Executive Summary
- Product Overview
- Product profile: Advair
- Product profile: Asmanex
- Product profile: Breo
- Product profile: Cinqair
- Product profile: Dulera
- Product profile: Flovent
- Product profile: Flutiform
- Product profile: Nucala
- Product profile: Pulmicort
- Product profile: Singulair
- Product profile: Spiriva
- Product profile: Symbicort
- Product profile: Xolair

PIPELINE: ASTHMA

- Executive Summary
- Clinical Pipeline Overview
- Early-Phase Opportunities
- Comparator Therapy
- Clinical Trial Design
- Product profile (late stage): QVM1
- Product profile (late stage): benralizumab
- Product profile (late stage): dupilumab
- Product profile (late stage): lebrikizumab
- Product profile (late stage): masitinib
- Product profile (late stage): tralokinumab
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll